{"protocolSection": {"identificationModule": {"nctId": "NCT01167153", "orgStudyIdInfo": {"id": "CVAA489ACN02"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Effectiveness of Valsartan/Amlodipine (EXforge\u00ae) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients", "officialTitle": "A 12 Weeks, Multi-center, Open Label, Randomized, Active Drug Parallel Control Trial to Compare the Effectiveness of Valsartan/Amlodipine and Nifedipine in Treating Chinese Hypertensive Patients Not Respond to Mono Antihypertensive Treatment", "acronym": "EXAM"}, "statusModule": {"statusVerifiedDate": "2012-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-05"}, "primaryCompletionDateStruct": {"date": "2011-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-07-20", "studyFirstSubmitQcDate": "2010-07-21", "studyFirstPostDateStruct": {"date": "2010-07-22", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-04-19", "resultsFirstSubmitQcDate": "2012-05-31", "resultsFirstPostDateStruct": {"date": "2012-06-01", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-05-31", "lastUpdatePostDateStruct": {"date": "2012-06-01", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study was to compare the efficacy and safety of Valsartan/Amlodipine (EXforge\u00ae) with nifedipine, as well as vascular function index."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension", "Valsartan Amlodipine single pill combination", "BP control", "ABPM", "Hypertensive patients not adequately controlled by mono antihypertensive drugs"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 564, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Valsartan/amlodipine", "type": "EXPERIMENTAL", "description": "Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.", "interventionNames": ["Drug: Valsartan/Amlodipine"]}, {"label": "Nifedipine", "type": "ACTIVE_COMPARATOR", "description": "Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.", "interventionNames": ["Drug: Nifedipine"]}], "interventions": [{"type": "DRUG", "name": "Valsartan/Amlodipine", "description": "Valsartan/Amlodipine 80/5mg single pill combination (SPC)", "armGroupLabels": ["Valsartan/amlodipine"], "otherNames": ["Exforge\u00ae"]}, {"type": "DRUG", "name": "Nifedipine", "description": "Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg", "armGroupLabels": ["Nifedipine"], "otherNames": ["Adalat"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at the Study End Point (12 Weeks)", "description": "The sitting blood pressure was trough value (23-26 hours after drug administration) measured by sphygmomanometer. Blood pressure was measured on both arms and the arm with higher mean sitting diastolic blood pressure (MSDBP) was used at visit 1 and following visits. Measurement of blood pressure was carried out 3 times at each visit on the selected arm. The results and mean value of three sitting blood pressures were recorded for analysis.", "timeFrame": "Baseline, 12 weeks"}, {"measure": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at the Study End Point (12 Weeks)", "description": "The sitting blood pressure was trough value (23-26 hours after drug administration) measured by sphygmomanometer. Blood pressure was measured on both arms and the arm with higher msDBP was used at visit 1 and following visits. Measurement of blood pressure was carried out 3 times at each visit on the selected arm. The results and mean value of three sitting blood pressures were recorded for analysis.", "timeFrame": "Baseline, 12 weeks"}], "secondaryOutcomes": [{"measure": "Percentage of Patients With Effective Systolic Blood Pressure (SBP) Control Rate and Effective Diastolic Blood Pressure (DBP) Control Rate at the Study End Point (12 Weeks)", "description": "Effective SBP control rate was defined as proportion of subjects in whom MSSBP \\< 140 mmHg or MSSBP reduction \u2265 20 mmHg from baseline.\n\nEffective DBP control rate was defined as proportion of subjects in whom MSDBP \\< 90 mmHg or MSDBP reduction \u226510 mmHg from baseline.", "timeFrame": "Baseline, 12 weeks"}, {"measure": "Percentage of Patients in Whom Blood Pressure Target Was Achieved at the Study End Point at 12 Weeks", "description": "Blood Pressure (BP) target was defined as mean sitting BP\\<140/90 mm Hg in non-diabetic patients and\\<130/80 mm Hg in diabetic patients at 12 weeks.", "timeFrame": "12 weeks"}, {"measure": "Change From Baseline in Orthostatic SBP and DBP at 12 Weeks", "description": "The arm with higher sitting blood pressure was selected for all examinations throughout the study. Orthostatic blood pressure was measured when subject stood for 1 minute. Orthostatic blood pressures were measured at screening and each visit.", "timeFrame": "Baseline, 12 weeks"}, {"measure": "Change From Baseline in Sitting Pulse at 12 Weeks", "description": "Sitting pulse was measured by sphygmomanometer after subject sat for 5 minutes at clinic during each visit.", "timeFrame": "Baseline, 12 weeks"}, {"measure": "Change From Baseline in Orthostatic Pulse at 12 Weeks", "description": "Orthostatic pulse was measured by sphygmomanometer when subject stood for 1 minute at clinic during each visit.", "timeFrame": "Baseline, 12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female adult outpatients had uncontrolled hypertension at both screening and randomization despite current antihypertensive monotherapy (initial dose of Angiotensin Receptor Blockers (ARB), Angiotensin Converting Enzyme Inhibitors (ACEI), Calcium Channel Blockers (CCB), diuretics or \u03b2 receptor blocker)\n\nExclusion Criteria:\n\n* Systolic BP (SBP) level \u2265160 mm Hg (\u2265160 mm Hg in diabetics) or a diastolic BP (DBP) level \u2265110 mm Hg (\u2265100 mm Hg in diabetics) at any time between screening and randomization.\n* Patients with type 1 diabetes or poorly controlled type 2 diabetes (glycosylated hemoglobin \\>8.0%)\n* Patients had evidence of hepatic disease or renal impairment\n* Other exclusion criteria included evidence of secondary hypertension or history of cardio-vascular disease.\n* Women who were pregnant, nursing, or of childbearing potential and not using acceptable contraception.\n\nOther protocol-defined inclusion/exclusion criteria applied.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Pharmaceuticals", "city": "Beijing", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}]}, "referencesModule": {"references": [{"pmid": "33734121", "type": "DERIVED", "citation": "Xu SK, Zeng WF, Li Y, Chen LL, Xie JH, Wang JG. Effects of the valsartan/amlodipine combination and nifedipine gastrointestinal therapeutic system monotherapy on brachial pulse pressure and radial augmentation index in hypertensive patients. Blood Press Monit. 2021 Aug 1;26(4):251-256. doi: 10.1097/MBP.0000000000000527."}, {"pmid": "23963546", "type": "DERIVED", "citation": "Wang JG, Zeng WF, He YS, Chen LL, Wei M, Li ZP, Zhang BW, Li Y; EXAM Investigators. Valsartan/amlodipine compared to nifedipine GITS in patients with hypertension inadequately controlled by monotherapy. Adv Ther. 2013 Aug;30(8):771-83. doi: 10.1007/s12325-013-0048-x. Epub 2013 Aug 21."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Valsartan/Amlodipine", "description": "Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}, {"id": "FG001", "title": "Nifedipine", "description": "Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "282"}, {"groupId": "FG001", "numSubjects": "282"}]}, {"type": "Intention to Treat (ITT)", "achievements": [{"groupId": "FG000", "numSubjects": "272"}, {"groupId": "FG001", "numSubjects": "268"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "264"}, {"groupId": "FG001", "numSubjects": "249"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "33"}]}], "dropWithdraws": [{"type": "Non-effective therapy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "AE including clinical laboratory AE", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "Hypotension", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Non-compliance to concomitant medication", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Investigator initiation withdrawal,Other", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal consent", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Subject initiation withdrawal, Other", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "8"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Valsartan/Amlodipine", "description": "Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}, {"id": "BG001", "title": "Nifedipine", "description": "Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "272"}, {"groupId": "BG001", "value": "268"}, {"groupId": "BG002", "value": "540"}]}], "measures": [{"title": "Age Continuous", "description": "demographic measures were based on intent to treat (ITT) population. One patient was missing from Nifedipine arm for Age, continuous measurement.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.8", "spread": "8.59"}, {"groupId": "BG001", "value": "53.1", "spread": "8.72"}, {"groupId": "BG002", "value": "53.5", "spread": "8.63"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "135"}, {"groupId": "BG001", "value": "135"}, {"groupId": "BG002", "value": "270"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "137"}, {"groupId": "BG001", "value": "133"}, {"groupId": "BG002", "value": "270"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at the Study End Point (12 Weeks)", "description": "The sitting blood pressure was trough value (23-26 hours after drug administration) measured by sphygmomanometer. Blood pressure was measured on both arms and the arm with higher mean sitting diastolic blood pressure (MSDBP) was used at visit 1 and following visits. Measurement of blood pressure was carried out 3 times at each visit on the selected arm. The results and mean value of three sitting blood pressures were recorded for analysis.", "populationDescription": "ITT (intention to treatment) population: all randomised subjects who had baseline assessment and at least one assessment record of MSSBP after baseline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline, 12 weeks", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine", "description": "Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}, {"id": "OG001", "title": "Nifedipine", "description": "Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "267"}, {"groupId": "OG001", "value": "265"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-16.8", "spread": "11.69"}, {"groupId": "OG001", "value": "-10.6", "spread": "12.02"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at the Study End Point (12 Weeks)", "description": "The sitting blood pressure was trough value (23-26 hours after drug administration) measured by sphygmomanometer. Blood pressure was measured on both arms and the arm with higher msDBP was used at visit 1 and following visits. Measurement of blood pressure was carried out 3 times at each visit on the selected arm. The results and mean value of three sitting blood pressures were recorded for analysis.", "populationDescription": "ITT (intention to treatment) population: all randomised subjects who had baseline assessment and at least one assessment record of MSDBP after baseline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline, 12 weeks", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine", "description": "Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}, {"id": "OG001", "title": "Nifedipine", "description": "Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "267"}, {"groupId": "OG001", "value": "265"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.5", "spread": "8.52"}, {"groupId": "OG001", "value": "-4.8", "spread": "8.89"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Effective Systolic Blood Pressure (SBP) Control Rate and Effective Diastolic Blood Pressure (DBP) Control Rate at the Study End Point (12 Weeks)", "description": "Effective SBP control rate was defined as proportion of subjects in whom MSSBP \\< 140 mmHg or MSSBP reduction \u2265 20 mmHg from baseline.\n\nEffective DBP control rate was defined as proportion of subjects in whom MSDBP \\< 90 mmHg or MSDBP reduction \u226510 mmHg from baseline.", "populationDescription": "ITT (intention to treatment) population: all randomised subjects who had baseline assessment and at least one assessment record of effective BP control after baseline.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline, 12 weeks", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine", "description": "Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}, {"id": "OG001", "title": "Nifedipine", "description": "Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "267"}, {"groupId": "OG001", "value": "265"}]}], "classes": [{"title": "Achieving Effective SBP Control", "categories": [{"measurements": [{"groupId": "OG000", "value": "82.40"}, {"groupId": "OG001", "value": "63.40"}]}]}, {"title": "Achieving Effective DBP Control", "categories": [{"measurements": [{"groupId": "OG000", "value": "92.88"}, {"groupId": "OG001", "value": "76.98"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients in Whom Blood Pressure Target Was Achieved at the Study End Point at 12 Weeks", "description": "Blood Pressure (BP) target was defined as mean sitting BP\\<140/90 mm Hg in non-diabetic patients and\\<130/80 mm Hg in diabetic patients at 12 weeks.", "populationDescription": "ITT (intention to treatment) population: all randomised subjects who had baseline assessment and at least one assessment record of blood pressure control after baseline", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine", "description": "Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}, {"id": "OG001", "title": "Nifedipine", "description": "Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "267"}, {"groupId": "OG001", "value": "265"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "79.03"}, {"groupId": "OG001", "value": "57.36"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Orthostatic SBP and DBP at 12 Weeks", "description": "The arm with higher sitting blood pressure was selected for all examinations throughout the study. Orthostatic blood pressure was measured when subject stood for 1 minute. Orthostatic blood pressures were measured at screening and each visit.", "populationDescription": "ITT (intention to treatment) population: all randomised subjects who had baseline assessment and at least one assessment record of orthostatic SBP and DBP after baseline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline, 12 weeks", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine", "description": "Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}, {"id": "OG001", "title": "Nifedipine", "description": "Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "266"}, {"groupId": "OG001", "value": "265"}]}], "classes": [{"title": "Orthostatic diastolic blood pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.2", "spread": "9.43", "lowerLimit": "-8.2172", "upperLimit": "-6.2177"}, {"groupId": "OG001", "value": "-3.3", "spread": "9.58", "lowerLimit": "-4.2475", "upperLimit": "-2.2442"}]}]}, {"title": "Orthostatic systolic blood pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.3", "spread": "13.86", "lowerLimit": "-14.3985", "upperLimit": "-11.4312"}, {"groupId": "OG001", "value": "-8.6", "spread": "13.98", "lowerLimit": "-10.4851", "upperLimit": "-7.5122"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sitting Pulse at 12 Weeks", "description": "Sitting pulse was measured by sphygmomanometer after subject sat for 5 minutes at clinic during each visit.", "populationDescription": "ITT (intention to treatment) population: all randomised subjects who had baseline assessment and at least one assessment record of sitting pulse rate after baseline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats/min", "timeFrame": "Baseline, 12 weeks", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine", "description": "Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}, {"id": "OG001", "title": "Nifedipine", "description": "Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "267"}, {"groupId": "OG001", "value": "264"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "8.49"}, {"groupId": "OG001", "value": "0.0", "spread": "8.22"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Orthostatic Pulse at 12 Weeks", "description": "Orthostatic pulse was measured by sphygmomanometer when subject stood for 1 minute at clinic during each visit.", "populationDescription": "ITT (intention to treatment) population: all randomised subjects who had baseline assessment and at least one assessment record of orthostatic pulse rate after baseline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats/min", "timeFrame": "Baseline, 12 weeks", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine", "description": "Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}, {"id": "OG001", "title": "Nifedipine", "description": "Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "266"}, {"groupId": "OG001", "value": "264"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "8.93"}, {"groupId": "OG001", "value": "0.4", "spread": "8.48"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "Safety analysis population: all randomised subjects who administrated at least one dose of investigational drug.", "eventGroups": [{"id": "EG000", "title": "Valsartan/Amlodipine", "description": "Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 282, "otherNumAffected": 14, "otherNumAtRisk": 282}, {"id": "EG001", "title": "Nifedipine", "description": "Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.", "seriousNumAffected": 1, "seriousNumAtRisk": 282, "otherNumAffected": 32, "otherNumAtRisk": 282}], "seriousEvents": [{"term": "Unstable Blood Pressure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 282}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 282}]}], "otherEvents": [{"term": "Dizzy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 282}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 282}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 282}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 282}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000068756", "term": "Valsartan"}, {"id": "D000009543", "term": "Nifedipine"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M12483", "name": "Nifedipine", "asFound": "Ibrutinib", "relevance": "HIGH"}, {"id": "M319", "name": "Amlodipine, Valsartan Drug Combination", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}